leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PRESS RELEASE

...see all

Global Pharmaceutical Excipients Market Set To Grow To $8.5bn By 2022

LONDON, UK. November 2017: Visiongain has launched a new pharma report Global Pharmaceutical Excipients Market Forecast to 2027: Plant-Based, Animal Chemistry, Mineral, Synthetic, Oral Application, Topical Application, Parental Application, Other Application, Binders, Diluents, Glidants, Disintegrant, Others.

The pharmaceutical industry is facing various challenges such as patent cliff, strict regulations and reduced healthcare spending; all these factors are hindering the development of new drugs. Novel excipients offer several opportunities to overcome these challenges. Novel excipients can be used to reformulate approved drugs and also improve the quality and safety of the drugs as well as reducing manufacturing cost. Manufacturers of generic drugs are now mainly focusing on reformulating and reintroducing their products with a cost-effective process to develop super generic drugs and to extent patents. Hence, various important steps are taken by key players such as modification in design and dosage forms, increasing focus on quality by design, and use of excipients in reformulation of drugs.

The lead analyst of the report commented Pharmaceutical industry is highly dependent on the development and discovery of new molecules for the replacement of old drugs revenue stream that are going towards patent expiry. Therefore, drug formulators and innovators are mainly focusing on developing new chemical entities. Similarly, narrow pipeline of new chemical excipients, increasing preference of manufacturers for the direct compression (DC) process and technological advancement in tablets manufacturing, are some of the other factors that will give opportunity for the development of high-functionality excipients.”

Leading companies featured in the report include Evonik Industries AG, BASF SE, Innophos Holdings Inc., The Lubrizol Corporation, The DOW Chemical Company, Wacker Chemie AG, Ashland Inc.

 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.
 

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close